Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2017-10-17
2021-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to ascertain if brain imaging with FFC MRI yields any useful information in the diagnosis and evaluation of Alzheimer's disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Composite MR Neuroimaging Marker for Alzheimer's Disease
NCT01615666
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259
Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients
NCT07004140
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150
11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation
NCT02811744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Potential participants will be approached by letter by their clinician. The purpose of this study will be explained to them and they will be asked for signed informed consent.
Communication between the clinical team and FFC-MRI research team will ensure that any appointment for FFC-MRI is made at a time that is convenient for the patient and clinical team.
The aim is to recruit 25 individuals with AD and 25 age matched controls.
FFC-MRI images will be acquired on dedicated equipment specifically built for the purpose of imaging human volunteers and patients. Where clinically appropriate patents will undergo other imaging procedures as part of their normal NHS care.
FFC-MRI will be compared standard clinical care data to identify regions of interest for quantitative analysis of FFC MRI data.
Anonymous personal information will be collected from the NHS patient records for stratification of the results (such as age, sex or relevant examination results)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's patients
Patient diagnosed with early onset Alzheimer's disease.
FFC-MRI scan
Undergo one FFC-MRI scan.
Control
Healthy volunteers that do not have Alzheimer's disease.
FFC-MRI scan
Undergo one FFC-MRI scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FFC-MRI scan
Undergo one FFC-MRI scan.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Controls will be participants without known cognitive impairment or Alzheimer's disease.
* Subjects capable of giving informed consent.
* Age 21 and above
Exclusion Criteria
* Claustrophobia
* Waist circumference larger than 102 cm, due to the limited bore size of the scanner.
* Restrictions to mobility such that patients are unable to be positioned in scanner by trained research radiographer e.g. severe kyphosis
* Cognitive impairment of sufficient severity that the participant does not have capacity to give informed consent
* Pregnancy
* Persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs
* Dementia of sufficient severity that the participant cannot give informed consent
21 Years
120 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aberdeen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biomedical Physics Building, Foresterhill Health Campus
Aberdeen, Scotland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2-031-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.